Eloralintide paired with tirzepatide produces added weight loss in type 2 diabetes
In a phase 2 trial, an investigational amylin receptor agonist used together with tirzepatide led to weight loss of as much as 23.3% in adults with type 2 diabetes and obesity.
6 min read Published